EMDR in Spider Phobia: Work Mechanisms and Treatment Outcome

Sponsor
University of Regensburg (Other)
Overall Status
Completed
CT.gov ID
NCT02973919
Collaborator
(none)
53
2
14.1

Study Details

Study Description

Brief Summary

The goal of this study is to increase the efficiency of exposure in virtual reality (VR).

Based on the EMDR research the investigators would like to show that the implementation of eye movements during the VR exposure results in a faster physiological relaxation response among probands with spider phobia, which has a positive effect on the subjective and behavioral efficacy of the VR exposure.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Eye Movement Desensitization and Reprocessing Therapy
  • Behavioral: Virtual Reality Exposure Therapy
N/A

Detailed Description

The VR paradigm consists of one room with a spider in it. The proband is supposed to look at it for a few minutes. This exposure is repeated several times.

In the experimental group a ball appears during the exposure, that moves horizontally across the room. The probands are supposed to follow this movement with their eyes.

EDA, EKG and respiration are being recorded. Furthermore the subjective and behavioral spider phobia is measured before, during and after the exposure to determine occurring changes.

Study Design

Study Type:
Interventional
Actual Enrollment :
53 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
EMDR in Spider Phobia: Work Mechanisms and Treatment Outcome
Study Start Date :
Jul 1, 2015
Actual Primary Completion Date :
Dec 1, 2015
Actual Study Completion Date :
Sep 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Eye movements

Eye Movement Desensitization and Reprocessing Therapy + virtual reality exposure therapy

Behavioral: Eye Movement Desensitization and Reprocessing Therapy
In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, & Renssen, 1999; de Jongh, Holmshaw, Carswell, & van Wijk, 2011; Lapsekili & Yelboga, 2014; Muris, Merckelbach, van Haaften, & Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).

Behavioral: Virtual Reality Exposure Therapy
Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger & Pauli, 2011).

Active Comparator: Control

virtual reality exposure therapy

Behavioral: Virtual Reality Exposure Therapy
Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger & Pauli, 2011).

Outcome Measures

Primary Outcome Measures

  1. Change in Behavioral Assessment Test (BAT) in vivo [5 minutes before, 5 minutes after intervention and during folow up (2 weeks post Intervention)]

    expected fear just before getting started and actually present fear just before finishing

Secondary Outcome Measures

  1. Skin Conductance Reactivity (SCR) [during the VR-session]

  2. Electrocardiogram (ECG) [during the VR-session]

    providing the Heart Rate (HR)

  3. manipulation check electrode below the right eye (M. orbicularis oculi) [during the VR- exposure sessions (5 min x 4 sessions)]

    for registering eye movements

  4. Change in Subjective Fear Ratings [1 min before and during ( each minute) exposure in Virtual Reality]

    Subjective Units of Disturbance Scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • the Structured Clinical Interview for DSM-IV (SCID, First et al., 2002; applied German translation: Strukturiertes Klinisches Interview für DSM-IV, Achse I, SKID I, Wittchen et al., 1997), in order to get a reliable diagnosis of spider phobia
Exclusion Criteria:
  • pregnancy

  • current psychopharmacological medication

  • current involvement in psychiatric- or psychotherapeutic treatment

  • cardiovascular or neurological diseases

  • color blindness

  • hearing disorders

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Regensburg

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shiban Youssef, Phd, University of Regensburg
ClinicalTrials.gov Identifier:
NCT02973919
Other Study ID Numbers:
  • URegensburg
First Posted:
Nov 28, 2016
Last Update Posted:
Nov 28, 2016
Last Verified:
Nov 1, 2016
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 28, 2016